Summary sheet
The project will finance the development of a new technology providing pharma companies access to utilise the clinical information embedded within Electronic Health Records (EHR)
The aim is to support the development of a new technology providing access to utilise the clinical information embedded within Electronic Health Records.
The project concerns artificial intelligence (AI) and real-world evidence data (RWE). As such the projects fits into Digital health. Digital health is a broad concept that, among others, covers the health data analysis and application in systems based on big data, for instance for epidemiological research and AI-enabled diagnosis support. The current project will develop solutions related but not limited to analysis of RWE data from electronic health records (EHR). Digitalisation is crucial to EU's competitiveness, where EU is aiming to catch-up with other regions of the World. This Project would further aid to accelerate adoption of digital technologies in the EU, related to R&D, healthcare and digital innovation. As such, through the financing of this Project aiming to facilitate increased investments in digital innovation the EIB is helping to bridge the digital gap between EU and US, e.g., and the digital divide within EU
The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.
The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB's guidelines for private sector projects. Further details will be verified during the project due diligence.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications